CNX Therapeutics completed the acquisition of Sativex from Jazz Pharmaceuticals.

CNX Therapeutics, a distributor of neurological, psychiatric, and emergency hospital treatments, completed the acquisition of Sativex, is indicated for symptom improvement in adult patients, from Jazz Pharmaceuticals, a specialty biopharmaceutical company that focuses on developing, manufacturing, and commercializing innovative drugs. Financial terms were not disclosed. “Our established CNS infrastructure and deep therapeutic expertise made this acquisition a strategic fit as we continue building our European specialty portfolio. We’re focused on ensuring seamless continuity of access for patients who rely on this treatment,” Ben Moore, CNX Therapeutics, Vice President of Corporate Development.